A Winter Holiday Celebration – 12/15/23

In-Person this Year!
Enjoy Dinner, Gifts, Fellowship and Fun
We’re so excited to announce our in-person Winter Holiday Celebration! Join us for crafts, games, Santa, and much more!
For questions email pbarrow@marylandsicklecelldisease.org or call Petronella Barrow at 410-465-4822.

Registration for this event is now closed.

This event was made possible by the support from:
Kamryn Lambert Foundation
Towson University Honors Helping Hands
The Global Blood Therapeutics, Inc. corporate logo is a registered trademark of Global Blood Therapeutics, Inc., a wholly owned subsidiary of Pfizer Inc. © 2023 Global Blood Therapeutics, Inc. All Rights Reserved.

Share this post

CONTACT US
KEEP IN TOUCH
Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

Breaking News

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

On December 8, 2023, “The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy."